Amoéba taps shareholders for €10M in quick re-raise before cosmetics sale
What's the deal? French greentech Amoéba is raising about €10 million through a rights issue open to all shareholders, priced at €0.30 per new share with warrants attached. The money will fund the commercial launch of its biocontrol business and prepare the sale or licensing of its Willa cosmetics platform.
Why now? The issue is the second leg of a roughly €18 million financing plan announced in September. Amoéba had just raised €7.9 million in a private placement, including €3 million from shareholder-creditor Nice & GreenDealroom has a profile for this one. Try Dealroom → through debt conversion, lifting its stake to 24.9%.
What's the endgame? Amoéba, which develops microbiological solutions based on the patented use of amoebae, wants to become a major player in biocontrol. It cites contracts signed with Koppert and SyngentaDealroom has a profile for this one. Try Dealroom →, and targets potential revenue of €80 million by 2032.
Why it matters: The company says this should be its last appeal to the market before reaching financial self-sufficiency, projected for 2029. The proceeds are meant to cover costs through September 2027, after which monetising Willa is intended to take over the financing.
What could go wrong? That handover is not guaranteed. Future financing depends on a Willa deal that has yet to close, and the discounted rights issue with warrants carries dilution risk. Amoéba had secured commitments for about 75% of its target at launch.
What's next? Subscriptions run until October 23, 2026. Each existing share grants three preferential subscription rights, with one share warrant attached per new share.
The signal: The quick re-raise buys time for a business still proving its commercial model, not proof of a growth trajectory. For now, Amoéba is betting that rising sales and the value of its cosmetics asset can carry it where market rounds alone no longer can.
Read more: webdisclosure.com
Image credit: Generated with Gemini
